Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
eli lilly
indiana blog main
indiana top stories
life sciences
national blog main
national top stories
novartis
3
×
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
cancer
clinical trials
detroit blog main
detroit top stories
fremanezumab
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
teva pharmaceutical
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
adalimumab (humira)
aducanumab
aduro biotech
affordable care act
alder biopharmaceuticals
alez azar
What
approval
3
×
drug
fda
medicines
new
address
amgen
approves
bio
biogen’s
biopharmaceutical
blueprint
cancer
candidates
carries
certain
class
companies
convo
designed
developed
earlier
failures
genetic
gets
head
latest
littered
migraine
nash
news
nod
pain
pass
preventive
price
remains
ret
road
roundup
Language
unset
Current search:
novartis
×
approval
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
